Item 2.01. Completion of Acquisition or Disposition of Assets.

On November 10, 2022, the Asset Sale was consummated and, in accordance with the Asset Purchase Agreement, Cardurion paid to Imara an upfront cash payment of $34,750,000 upon closing of the Asset Sale. As previously announced, the purchase price also consists of a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement.

The foregoing description of the Asset Sale and the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Asset Purchase Agreement, which was filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on September 7, 2022 and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 9, 2022, the Company held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the Company's stockholders voted on the proposals set forth below relating to the Asset Sale. The proposals are described in more detail in the Company's definitive proxy statement, filed with the SEC on October 7, 2022. As of the close of business on October 5, 2022, the record date for the Special Meeting, there were 26,287,264 shares of Company common stock issued and outstanding. At the Special Meeting, 18,426,608 shares of Company common stock were represented virtually or by proxy and, therefore, a quorum was present. The final voting results regarding each proposal are set forth below.

Proposal No. 1: To approve the sale by the Company to Cardurion of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program, pursuant to the terms of the Asset Purchase Agreement, for an upfront cash payment of $34,750,000 upon closing of the Asset Sale (in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms and conditions of the Asset Purchase Agreement (the "Asset Sale Proposal").

This proposal was approved by the requisite vote of the Company's stockholders.



   For       Against   Abstain   Broker Non-Votes
18,366,825   11,907    47,876           0

Proposal No. 2: To approve the adjournment of the Special Meeting, if necessary and to the extent permitted by the Asset Purchase Agreement, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Asset Sale Proposal. This proposal was approved by the requisite vote of the Company's stockholders, but adjournment of the Special Meeting was unnecessary because there was a quorum present and there were sufficient votes received at the time of the Special Meeting to approve the Asset Sale Proposal.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(b) The Company intends to file the pro forma financial information required by Item 9.01(b) as part of an amendment to this Current Report on Form 8-K no later than four business days after the closing of the Asset Sale.



(d) Exhibits

Exhibit No.       Description

2.1*                Asset Purchase Agreement, dated September 6, 2022, between
                  Imara Inc. and Cardurion Pharmaceuticals, Inc. (incorporated by
                  reference to Exhibit 2.1 of the Company's Current Report on Form
                  8-K filed on September 7, 2022).

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document).

* Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of

Regulation S-K. The Company hereby undertakes to furnish supplementally copies

of any of the omitted exhibits and schedules upon request by the SEC; provided,

however, that the Company may request confidential treatment pursuant to Rule

24b-2 the Securities Exchange Act of 1934, as amended, for any exhibits or

schedules so furnished.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses